Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in Bone Metastatic CRPC
NCT02204943Phase 1Completed
- Sponsor
- Duke University
- Start
- May 2015
- Primary completion
- Jul 2017
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Duke University. Started May 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02204943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204943.